The overwhelming majority of patient accrual to City of Hope (COH)-sponsored trials without other sources of peer-reviewed support was to Phase l/ll and pilot trials by COM clinical investigators. This was made possible by the protocol specific research support (PSRS) of the CCSG. This resource has played an important role in providing preliminary data for new R01 and P01 proposals. These protocols all are subject to review by the Clinical Protocol Review and Monitoring Committee (CPRMC), as described under the PRMS section. Funding for the PSRS staff will provide the Cancer Center with a stable core of expert staff who are highly qualified to support the conduct and completion of innovative, short-term feasibility studies originating from COHCCC Programs. The studies supported by PSRS are the foundation of the programs in Hematologic Malignancies, Developmental Cancer Therapeutics and Cancer Immunotherapeutics. More than 500 patients per year were accrued to therapeutic clinical trials by these three programs over the last grant cycle;in FY 2006 this accrual grew to 652 patients enrolled on therapeutic trials. Accrual to investigator-initiated, COH-sponsored trials (without other peer-reviewed sources of support) comprised 34% of the patient volume enrolled onto interventional trials in FY 2006. The prioritization of the usage of the resources provided by PSRS (and the oversight of the budget) is performed initially within the clinical research programs themselves and then by the review provided by the Clinical Research Governance Board, chaired by Dr. Robert Figlin. Oversight of the CRAs involved in these trials occurs at several levels including that provided by the clinical research program leaders, the protocol Principal Investigators, and by the Clinical Protocol Management Core (CPMC) training and quality assurance process. All of the CRAs requested in support of protocol specific research from the CCSG are part of the larger, centralized pool of CRAs overseen and administered by the CPMC. Funding is requested to support three full-time equivalents (FTEs) spread over 6 CRAs to cover the broad spectrum of trials and programs, while allowing diseasespecific focus for protocol management of funded trials as well. These CRAs are responsible for protocol monitoring, data collection and data quality control for our in-house Phase I and pilot studies. They help ensure the success of the clinical studies by providing eligibility checks of patients prior to enrollment, assisting in meeting accrual goals, providing follow-up and recording accurate complete subject data.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-26
Application #
8182242
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-12-01
Budget End
2009-11-30
Support Year
26
Fiscal Year
2009
Total Cost
$162,152
Indirect Cost
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Gong, Jun; Salgia, Ravi (2018) Managing Patients With Relapsed Small-Cell Lung Cancer. J Oncol Pract 14:359-366
Chen, Robert W; Palmer, Joycelynne M; Tomassetti, Sarah et al. (2018) Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. J Hematol Oncol 11:87
Romsdahl, Jillian; Blachowicz, Adriana; Chiang, Abby J et al. (2018) Characterization of Aspergillus niger Isolated from the International Space Station. mSystems 3:
Sen, Subha; He, Zhiheng; Ghosh, Shubhamoy et al. (2018) PRMT1 Plays a Critical Role in Th17 Differentiation by Regulating Reciprocal Recruitment of STAT3 and STAT5. J Immunol 201:440-450
Lueschow, Shiloh R; Stumphy, Jessica; Gong, Huiyu et al. (2018) Loss of murine Paneth cell function alters the immature intestinal microbiome and mimics changes seen in neonatal necrotizing enterocolitis. PLoS One 13:e0204967
Gu, Long; Lingeman, Robert; Yakushijin, Fumiko et al. (2018) The Anticancer Activity of a First-in-class Small-molecule Targeting PCNA. Clin Cancer Res 24:6053-6065
Zhao, Xingli; Zhang, Zhuoran; Moreira, Dayson et al. (2018) B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors. Mol Ther 26:695-707
Weitzel, Jeffrey N; Chao, Elizabeth C; Nehoray, Bita et al. (2018) Somatic TP53 variants frequently confound germ-line testing results. Genet Med 20:809-816
Ghose, Jayeeta; Viola, Domenico; Terrazas, Cesar et al. (2018) Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology 7:e1486948
Aslamy, Arianne; Oh, Eunjin; Olson, Erika M et al. (2018) Doc2b Protects ?-Cells Against Inflammatory Damage and Enhances Function. Diabetes 67:1332-1344

Showing the most recent 10 out of 1396 publications